Navigation Links
Mindray Announces Second Quarter 2012 Financial Results
Date:8/6/2012

SHENZHEN, China, Aug. 6, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2012. 

Highlights for Second Quarter 2012

  • Net revenues were $267.8 million, an increase of 23.3% over the second quarter of 2011.
  • Robust China sales growth of 27.1% to $115.3 million year-over-year, primarily driven by regular sales.
  • Strong international sales of $152.5 million, representing an increase of 20.5% from the same period last year. Emerging markets[1] and developed markets[2] achieved good sales growth of 21.1% and 19.7% year-over-year, respectively.
  • Non-GAAP gross margin was 57.8%, an improvement of 2.3% sequentially.
  • Non-GAAP net income was $59.5 million, a 19.4% increase over the second quarter of 2011.
  • Net operating cash generated during the quarter was $61.4 million, up a significant 81.6% compared to the same period last year.
  • Reagent revenues growth accelerated, contributing 34.4% to the in-vitro diagnostic business this quarter, compared to 28.4% in the same period last year and 31.5% in the prior quarter.
  • Mindray introduced five new products in the first half of 2012, including the latest high speed biochemistry analyzer, the BS-2000, a clinical biochemistry analyzer, the BS-480, an updated auto hematology analyzer, the BC-5390, a fully automatic urinary sediment analyzer, the EH-2050B Plus, and a new portable diagnostic color ultrasound system, the Z6.
  • In July, Mindray completed the acquisition of a controlling stake in Wuhan Dragonbio Surgical Implant Co., Ltd., a domestic medical orthopedic products provider.
  • "Despite the challenging environments in various international regions, we have once again achieved very solid performance in sales, profits and cash generation," commented Xu Hang, Mindray's chairman and co-chief executive officer. "All major geographical areas have delivered strong growth for the quarter. We are particularly encouraged by our good performance in developed markets, considering the volatility of those regions over the past year. We have also improved our gross margin and the healthy cash conversion cycle reflected our efforts in improving operational efficiency. In addition, we have launched new products in our IVD line and closed the orthopedics acquisition recently. Our reagent sales are continuing to accelerate. All of these are in line with the company's strategy to capture opportunities in the fast-growing consumable products markets. Going forward, we intend to prudently deploy our strong cash position and continue to look for attractive investment opportunities worldwide."

    SUMMARY – Second Quarter 2012 (in $ millions, except per-share data)

    Three Months EndedJune 302012

    2011

    % chgNet Revenues

    267.8

    217.3

    23.3%Revenues generated in China

    115.3

    90.7

    27.1%Revenues generated outside China

    152.5

    126.6

    20.5%Gross Profit

    153.6

    123.8

    24.1%Non-GAAP Gross Profit

    154.8

    125.2

    23.7%Operating Income

    55.9

    47.4

    17.8%Non-GAAP Operating Income

    63.5

    52.5

    20.9%EBITDA

    66.4

    56.9

    16.7%Net Income

    52.0

    44.8

    16.1%Non-GAAP Net Income

    59.5

    49.8

    19.4%Diluted EPS

    0.44

    0.37

    16.3%Non-GAAP Diluted EPS

    0.50

    0.42

    19.7%RevenuesMindray reported net revenues of $267.8 million for the second quarter, a 23.3% increase from $217.3 million in the second quarter of 2011. Net revenues generated in China in the second quarter increased 27.1% to $115.3 million from $90.7 million in the same period last year, while net revenues generated in the international markets in the second quarter increased 20.5% to $152.5 million from $126.6 million in the same period of 2011.

    Performance by SegmentPatient Monitoring & Life Support Products: Revenue in this segment increased 23.3% to $114.6 million from $93.0 million in the second quarter of 2011, contributing 42.8% to total net revenues in the second quarter of 2012.

    In-Vitro Diagnostic Products: Revenue in this segment increased 31.1% to $73.9 million from $56.4 million in the second quarter of 2011, contributing 27.6% to total net revenues in the second quarter of 2012. Reagents sales represented 34.4% of this segment's revenue.

    Medical Imaging Systems: Revenue in this segment increased 15.1% to $64.1 million from $55.7 million in the second quarter of 2011, contributing 24.0% to total net revenues in the second quarter of 2012.

    Others: Other revenues increased 24.4% to $15.1 million from $12.2 million in the second quarter of 2011, contributing 5.6% to total net revenues in the second quarter of 2012. They included service revenues from extended warranty, sales of accessories and service fees charged for post-warranty period repair services.

    Gross MarginSecond quarter gross profit was $153.6 million, a 24.1% increase from $123.8 million in the same period last year. Non-GAAP gross profit in the quarter was $154.8 million, a 23.7% increase from $125.2 million in the second quarter of 2011. Gross margin was 57.4% compared to 57.0% in the second quarter of 2011 and 54.9% in the first quarter of 2012. Non-GAAP gross margin was 57.8% compared to 57.6% in the second quarter of 2011 and 55.5% in the first quarter of 2012.

    Operating ExpensesSelling expenses for the quarter were $47.8 million, or 17.8% of total net revenues, compared to 18.6% in the second quarter of 2011 and 18.1% in the first quarter of 2012. Non-GAAP selling expenses were $45.5 million, or 17.0% of total net revenues, compared to 17.7% in the second quarter of 2011 and 17.5% in the first quarter of 2012.

    General and administrative expenses were $26.1 million, or 9.7% of total net revenues, compared to 8.0% in the second quarter of 2011 and 9.0% in the first quarter of 2012. Non-GAAP general and administrative expenses were $23.3 million, or 8.7% of the total net revenues, compared to 7.7% in the second quarter of 2011 and 8.7% in the first quarter of 2012.

    Research and development expenses were $23.9 million, or 8.9% of total net revenues, compared to 8.5% in the second quarter of 2011 and 11.1% in the first quarter of 2012. Non-GAAP research and development expenses were $22.5 million, or 8.4% of total net revenues, compared to 8.0% in the second quarter of 2011 and 10.7% in the first quarter of 2012.

    Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $6.0 million compared to $3.3 million in the second quarter of 2011 and $2.2 million in the first quarter of 2012.

    Operating income was $55.9 million, a 17.8% increase from $47.4 million in the second quarter of 2011. Non-GAAP operating income was $63.5 million, a 20.9% increase from $52.5 million in the second quarter of 2011. Operating margin was 20.9% compared to 21.8% in the second quarter of 2011 and 16.8% in the first quarter of 2012. Non-GAAP operating margin was 23.7% compared to 24.2% in the second quarter of 2011 and 18.5% in the first quarter of 2012. Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")Second quarter EBITDA increased 16.7% to $66.4 million from $56.9 million in the second quarter of 2011. Net IncomeNet income increased 16.1% to $52.0 million from $44.8 million in the second quarter of 2011. Non-GAAP net income increased 19.4% to $59.5 million from $49.8 million in the second quarter of 2011. Net margin was 19.4% compared to 20.6% in the second quarter of 2011 and 16.7% in the first quarter of 2012. Non-GAAP net margin was 22.2% compared to 22.9% in the second quarter of 2011 and 18.4% in the first quarter of 2012. Second quarter 2012 income tax expense was $10.0 million, representing an effective tax rate of 16.1%.

    Second quarter basic and diluted earnings per share were $0.45 and $0.44, respectively, compared to $0.38 and $0.37 in the same period last year. Basic and diluted non-GAAP earnings per share were $0.51 and $0.50, respectively, compared to $0.43 and $0.42 in the second quarter of 2011. Shares used in the computation of diluted earnings per share for the second quarter of 2012 were 119.4 million.

    Other Select DataAccounts receivable days were 64 days in the second quarter of 2012 compared to 79 days in the previous quarter. Inventory days were 87 days compared to 92 days in the previous quarter. Accounts payable days were 54 days, unchanged from the last quarter. Mindray calculates the above working capital days using the average of beginning and ending balances of the quarter.

    As of June 30, 2012, the company had $710.1 million in cash, cash equivalents and short-term investments, up 6.9% from $664.2 million as of March 31, 2012. Net cash generated from operating activities and net cash outflow for capital expenditures during the quarter were $61.4 million and $16.7 million, respectively.

    As of June 30, 2012, the company had approximately 6,800 employees.

    Business Outlook for Full Year 2012The company continues to expect its full year 2012 net revenues to grow at least 18% over those of the previous year.

    The company now expects its full year 2012 non-GAAP net income to grow at least 15% over the full year 2011 figure, up from its previous guidance of 13% year-over-year growth. This guidance excludes the tax benefits related to the National Key Software Enterprise status and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary. Mindray recorded the tax benefits of $7.6 million in the first quarter of 2011 as a result of receiving the National Key Software Enterprise status for year 2010. The PRC tax authority has not released the list of companies that are eligible for renewal of such status and thus we have not recorded any tax benefits in the first half of 2012. Due to the change in the review timing from once a year to once every two years, Mindray cannot determine at this time when the tax authority will release the list. Upon notice, the potential benefits will be included in the company's financial statements.

    The company expects its capital expenditure for 2012 to be around $90 million.

    The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

    "We are confident about delivering our revised financial targets for the year," commented Li Xiting, Mindray's president and co-chief executive officer. "We expect China and other emerging markets to continue to drive our top-line sales. However, we still believe certain regions could present headwinds for us due to political uncertainties, other local policy issues and FX fluctuations. We have done well in the developed markets this quarter. However, in light of the troubling developments in Europe, we are cautious and are working to ensure that we remain nimble in order to find the best opportunities in the region. Looking ahead, we will maintain our operational excellence and explore additional opportunities that will further accelerate Mindray's future growth and expansion."

    Conference Call InformationMindray's management will hold an earnings conference call at 8:00 AM on August 7, 2012 U.S. Eastern Time (8:00 PM on August 7, 2012 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    International Toll Free:United States:   +1-866-519-4004Hong Kong:
    800-930-346China:
    800-819-0121Local dial-in numbers:United States:
    +1-718-354-1231Hong Kong:
    +852-2475-0994 China:
    400-620-8038Passcode for all regions: MindrayA replay of the conference call may be accessed by phone at the following numbers until August 22, 2012.

    U.S. Toll Free:
    +1-866-214-5335U.S. Toll:
    +1-718-354-1232China Toll:
    400-692-0026Passcode:
    81-5908Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at: http://ir.mindray.com

    Use of Non-GAAP Financial Measures Mindray provides gross profit, selling expenses, general and administrative expenses, R&D expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense and acquired intangible assets amortization expense, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

    The company has reported for the second quarter of 2012 and provided guidance for full year 2012 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization expenses.
  • The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three months ended June 30, 2011 and 2012, respectively, in the attached financial information.

    Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2012, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, the uncertainty to determine at this time when the PRC tax authority will release the list of companies that are eligible for renewal of status of National Key Software Enterprise for the year 2011, that the potential benefits will be included in our financial statements upon such notice, that our reagent sales are continuing to accelerate, which is in line with the company's strategy to capture opportunities in the fast-growing consumable products markets, our intent to prudently deploy our strong cash position and continue to look for attractive investment opportunities worldwide, our expectation that China and other emerging markets will continue to drive our top-line sales, our belief that certain regions could present headwinds for us due to political uncertainties, other local policy issues and FX fluctuations, that we are cautious and are working to ensure that we remain nimble in order to find the best opportunities in Europe in light of the troubling developments in that region, and our expectation to maintain our operational excellence and explore additional opportunities that will further accelerate Mindray's future growth and expansion, are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 30, 2012. Our results of operations for the second quarter as of June 30, 2012 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

    All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

    About Mindray We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

    For investor and media inquiries please contact:

    In the U.S:

    Hoki Luk
    Western Bridge, LLC
    Tel: +1-646-808-9150
    Email: hoki.luk@westernbridgegroup.com

    In China:

    Cathy Gao
    Mindray Medical International Limited
    Tel: +86-755-8188-8023
    Email: cathy.gao@mindray.com


    [1]  Emerging markets represent the countries in all regions except for China and developed markets.

    [2]  Developed markets represent the North America and Western European countries.Exhibit 1MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in thousands)As of December 31, 2011As of June 30, 2012US$ US$ (Note 1) (unaudited) ASSETSCurrent assets:Cash and cash equivalents

    124,311247,985Short-term investments 

    479,173462,088Accounts receivable, net

    200,437194,346Inventories

    94,690113,850Value added tax receivables

    10,83320,457Other receivables

    16,59013,356Prepayments and deposits

    9,79211,111Deferred tax assets, net

    3,4834,624Total current assets

    939,3091,067,817Other assets

    7,3309,238Advances for purchase of plant and equipment

    6,2393,593Property, plant and equipment, net

    237,952243,578Land use rights, net 

    55,27254,351Intangible assets, net

    84,02984,768Goodwill

    128,840133,063Total assets

    1,458,9711,596,408LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Short-term bank loans

    50,47552,472Notes payable

    7,0134,835Accounts payable

    48,50168,368Advances from customers

    20,70018,293Salaries payable

    38,78437,207Other payables

    67,49979,218Income taxes payable

    16,84717,486Other taxes payable

    7,4124,849Total current liabilities

    257,231282,728Long-term bank loans

    35,02585,063Other long-term payables

    2,3553,401Deferred tax liabilities, net

    12,92514,38850,305102,852Shareholders' equity:Ordinary shares

    1515Additional paid-in capital

    486,314504,856Retained earnings

    566,184608,377Accumulated other comprehensive income

    100,13992,786Treasury stock

    (10,160)(6,345)Total shareholders' equity

    1,142,4921,199,689Non-controlling interests

    8,94311,139Total equity

    1,151,4351,210,828Total liabilities and shareholders' equity

    1,458,9711,596,408(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F. Exhibit 2MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Dollars in thousands, except for share and per share data)Three months ended June 30, Six months ended June 30, 2011201220112012US$ US$ US$ US$ (unaudited) (unaudited) (unaudited) (unaudited) Net revenues-PRC90,729115,294163,182207,134- International 126,553152,536235,004279,713Net revenues217,282267,830398,186486,847Cost of revenues (93,486)(114,208)(174,671)(212,900)Gross profit123,796153,622223,515273,947Selling expenses (40,416)(47,759)(74,088)(87,488)General and administrative expenses (17,437)(26,111)(31,864)(45,725)Research and development expenses (18,504)(23,877)(37,092)(48,154)Operating income47,43955,87580,47192,580Other income, net1,7523882,178973Interest income3,9777,2607,48615,698Interest expense(381)(1,287)(601)(1,978)Income before income taxes and non-controlling interests52,78762,23689,534107,273Provision for income taxes(7,931)(10,023)(6,968)(18,366)Net income 44,85652,21382,56688,907Less: Net income attributable to non-controlling interests(47)(206)(47)(313)Net income attributable to the Company44,80952,00782,51988,594Basic earnings per share0.380.450.720.76Diluted earnings per share0.370.440.700.74Shares used in the computation of:Basic earnings per share116,504,103116,547,129115,026,629116,283,063Diluted earnings per share119,653,716119,394,768118,275,625119,353,032 Exhibit 3MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Dollars in thousands)Three months ended June 30,Six months ended June 30, 2011201220112012 US$  US$  US$  US$  (unaudited)  (unaudited)  (unaudited)  (unaudited) Cash flow from operating activities:  Net income

    44,80952,00782,51988,594Adjustments to reconcile net income to net cash from operating activities

    9,62122,07821,93536,593  Changes in current assets and liabilities

    (20,647)(12,731)(38,373)(3,711)Net cash generated from operating activities33,78361,35466,081121,476Cash flow from investing activities:Acquisition cost, net of cash acquired

    (3,646)-(3,646)(2,739)Capital expenditures

    (17,039)(16,745)(44,355)(32,835)Proceeds from sale of short-term investments

    4,441-90,133144,395Increase in short-term investments and changes in others investing activities

    (40,915)(32,637)(152,264)(125,489)Net cash used in investing activities(57,159)(49,382)(110,132)(16,668)Cash flow from financing activities:Proceeds from bank loans

    34,9302,00034,93052,000Dividends paid

    (34,522)-(34,522)(46,401)Proceeds from exercise of options

    3,1124,6914,34714,138Cash contribution from non-controlling interests

    ---506Net cash generated from financing activities3,5206,6914,75520,243Net (decrease)/increase in cash and cash equivalents(19,856)18,663(39,296)125,051Cash and cash equivalents at beginning of period

    118,746231,010137,502124,311Effect of exchange rate changes on cash

    724(1,688)1,408(1,377)Cash and cash equivalents at end of period99,614247,98599,614247,985Exhibit 4MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES(Dollars in thousands, except for share and per share data)Three months ended June 30,Six months ended June 30,2011201220112012(unaudited)(unaudited)(unaudited)(unaudited) US$  US$  US$  US$ Non-GAAP net income49,84059,51092,06299,894Non-GAAP net margin22.9%22.2%23.1%20.5%Amortization of acquired intangible assets(1,783)(1,629)(3,550)(3,264)Deferred tax impact related to acquired intangible assets348368118Share-based compensation(3,282)(5,957)(6,061)(8,154)GAAP net income 44,80952,00782,51988,594GAAP net margin20.6%19.4%20.7%18.2%Non-GAAP basic earnings per share0.430.510.800.86Non-GAAP diluted earnings per share0.420.500.780.84GAAP basic earnings per share0.380.450.720.76GAAP diluted earnings per share0.370.440.700.74 Shares used in computation of:  Basic earnings per share 116,504,103116,547,129115,026,629116,283,063 Diluted earnings per share 119,653,716119,394,768118,275,625119,353,032Non-GAAP operating income52,50463,46190,082103,998Non-GAAP operating margin24.2%23.7%22.6%21.4%Amortization of acquired intangible assets(1,783)(1,629)(3,550)(3,264)Share-based compensation(3,282)(5,957)(6,061)(8,154)GAAP operating income47,43955,87580,47192,580GAAP operating margin21.8%20.9%20.2%19.0%Non-GAAP gross profit125,152154,796226,193276,245Non-GAAP gross margin57.6%57.8%56.8%56.7%Amortization of acquired intangible assets (1,153)(960)(2,297)(1,926)Share-based compensation(203)(214)(381)(372)GAAP gross profit123,796153,622223,515273,947GAAP gross margin57.0%57.4%56.1%56.3%Non-GAAP selling expenses(38,483)(45,472)(70,449)(83,838)Non-GAAP as % of total revenues17.7%17.0%17.7%17.2%Amortization of acquired intangible assets (630)(669)(1,253)(1,338)Share-based compensation(1,303)(1,618)(2,386)(2,312)GAAP selling expenses(40,416)(47,759)(74,088)(87,488)GAAP as % of total revenues18.6%17.8%18.6%18.0%Non-GAAP general and administrative expenses(16,742)(23,317)(30,670)(42,418)Non-GAAP as % of total revenues7.7%8.7%7.7%8.7%Share-based compensation(695)(2,794)(1,194)(3,307)GAAP general and administrative expenses(17,437)(26,111)(31,864)(45,725)GAAP as % of total revenues8.0%9.7%8.0%9.4%Non-GAAP research and development expenses(17,423)(22,546)(34,992)(45,991)Non-GAAP as % of total revenues8.0%8.4%8.8%9.4%Share-based compensation(1,081)(1,331)(2,100)(2,163)GAAP research and development expenses(18,504)(23,877)(37,092)(48,154)GAAP as % of total revenues8.5%8.9%9.3%9.9%Exhibit 5MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION
    AND AMORTIZATION(Dollars in thousands)Three months ended June 30,  Six months ended June 30,2011201220112012US$US$US$US$(unaudited)(unaudited)(unaudited)(unaudited)GAAP net income

    $

    44,80952,00782,51988,594Interest income(3,977)(7,260)(7,486)(15,698)Interest expense3811,2876011,978Provision for income tax7,93110,0236,96818,366Earnings before interest and taxes ("EBIT")49,14456,05782,60293,240Depreciation5,2137,45110,26114,041Amortization2,5462,9034,8695,792Earnings before interest, taxes, depreciation, and amortization ("EBITDA")56,90366,41197,732113,073
    '/>"/>

    SOURCE Mindray Medical International Limited
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Mindray to Report Second Quarter 2012 Financial Results on August 6, 2012
    2. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
    3. Mindray Medical to Present at AACC Clinical Lab Expo 2012
    4. Mindray Announces First Quarter 2012 Financial Results
    5. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
    6. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
    7. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    8. Isis Pharmaceuticals Announces Proposed Offering of $175 Million of Convertible Senior Notes
    9. Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
    10. Bausch + Lomb Announces Extension of Early Tender Date for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
    11. TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
    (Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
    (Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
    (Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
    (Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
    (Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
    Breaking Medicine News(10 mins):